Key

Inclusion Criteria:

- Adults over age 18 years of age with a life expectancy of at least 3 months

- Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB
(with pleural effusion), stage IV, or recurrence

- Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm
if measured by spiral CT)

- Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL
and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine
clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN,
AST ≤ 3 x ULN)

- D-dimer ≤ 2 x ULN

Key Exclusion Criteria:

- Small cell or mixed histology

- Known history of bleeding diathesis or coagulopathy

- Any current evidence of clinically significant bleeding defined as gross hematuria,
hemoptysis, or GI bleeding

- Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary
thromboembolism)

- Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease
unless disease had recurred after radiotherapy

- Radiotherapy within 2 weeks preceding Study Day 1

- Symptomatic or clinically active CNS disease or metastatic lesions

- Major surgery within 4 weeks of Study Day 1

- Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)

- Any history of angina pectoris, coronary artery disease or cerebrovascular accident,
or transient ischemic attack

- A history of any condition requiring anti-platelet therapy with the exception of
general cardiovascular prophylaxis with aspirin. Anti-platelet agents are prohibited
during the study.

- Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs, or steroids